string(38) ‘ realization of their full potential\. ‘
ACKNOWLEDGEMENT To start with, I would like to convey my deep gratitude to Allah the Almighty intended for giving myself the opportunity to conduct and successfully completing the term paper. We acknowledge my heartiest as a result of our reputable course instructor Md. Khairul Islam, Helper Professor, Division of Business Studies, Dhaka International School for supplying me the chance to carry out this report.
His valuable advice and criteria helped me a lot in preparing this record successfully. Normally the task of preparing this report could have been harder in part.
Second of all, I like to communicate my appreciation and thanks to the Personnel of Incepta Pharmaceutical drugs Ltd. pertaining to providing me the required data, support and suggestions concerning this Record. Executive Overview This survey details about a respected Pharmaceutical company of Bangladesh named Incepta Pharmaceuticals. The report traces the background from the company together with the production and marketing procedures. Incepta Drugs is one of the distinguished companies in Bangladesh. That starts it work by 1999 and till the organization is in the leading position.
The corporation has a crystal clear vision as well as its mission should be to fulfill their very own vision. The organization has level ofmanagement and these distinct level managers work together to improve the present current condition of the company. Incepta produces types of medicines and now the company is usually exporting medicines to thirty five countries. Incepta also maintain their sociable responsibilities intended for the enhancement of Bangladesh. Objectives from the Report The main objectives with the study should be learn how to prepare a report. Our honorable program teacher designates us to get ready this record so that inside the ob industry we canperform effectively and efficiently and in addition enlighten the goodwill of the university and our teachers. Other objectives of this report are: ¢ To share the lesson learns. ¢ To inform about the progress. ¢ To analyze the inputs resistant to the outputs. ¢ To talk the changes. ¢ Analyze the recommendations. ¢ Risk lowering preparation. ¢ To plan accordingly intended for up-coming period. ¢ To adopt quick decisions. Methodology from the Report For smooth and accurate examine everyone have to follow some rules , regulation. The analysis impute had been collected coming from two options.
The resources are i. Primary resources ii. Second sources Principal sources: Major sources of details are those that provide first hand accounts from the events, methods, or circumstances. In general, these are documents that had been created by witnesses or first recorders of these situations at about the time they happened. These info are accumulated from: ¢ Practical desk work ¢ One on one conversation with the officer ¢ Direct observations ¢ In person conversation together with the client Secondary sources: Second-hand, published accounts are called supplementary sources.
They can be called second sources since they are created following primary sources and they frequently use or talk about main sources. Secondary sources will give additional opinions on a past event or perhaps on a principal source. Secondary sources often have many replications which all of us collected by: ¢ Annual statement of firms ¢ Several publications of companies, ¢ Website Restrictions of the Study The study is principally based on supplementary data. The study is confined to only one developing firm that may be categorized into miscellaneous developing firm. The analysis is limited to corporate companies as cured as a example.
In the a shortage of more reliable and available data, this study is below taken just for short periods. This analyze leaves a short-run insurance coverage of durations sample pertaining to want to studying the immediate impact of changes in corporations as it was suitable for long-run analysis. Review of Related Literature Examination of Data Regarding Incepta Pharmaceutical drugs Ltd: Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in Bangladesh established back in 1999. The business has a very big manufacturing facility located by Savar, thirty-five kilometer away from the center of the capital metropolis Dhaka.
The corporation produces various kinds of serving forms that include tablets, supplements, oral liquids, ampoules, dry powder vials, powder pertaining to suspension, sinus sprays, eyesight drops, lotions, ointments, creams, gels, prefilled syringes, liquefied filled hard gelatin capsules, lyophilized shots etc . As its inception, Incepta has been introducing new and innovative goods in order to match unmet demand of the medical community. The focus has always been to create new, more technologically advanced elements and innovative dosage varieties to this nation.
The company focuses primarily on value added excessive technology dosage forms just like sustained launch tablets, quick mouth dissolving tablets, militant tablets, buffer coated delayed release tablets, prefilled syringe products, Insulin and Insulin analogue and biological goods, among others. They have established a modern research and development laboratory for the development of new, advanced dosage varieties for numerous drugs and devices just like poorly soluble drugs, dry powder inhalers, coated pellets, modified discharge products, preference masked planning etc .
Incepta has a incredibly competent sales force, which stimulates the expertise throughout the region. The company virtually covers almost every corner with the rural as well as urban part of Bangladesh. It includes its own large distribution network having 18 depots from coast to coast. The company contains a clear perspective to become a leading research centered dosage contact form manufacturing firm with global presence within a short period of your energy. With this view in mind the company started to expand their business in overseas markets.
Currently Incepta exports to 33 different countries around the world. With hundreds of brands registered in different countries, and many more inside the pipeline, Incepta is slowly but surely expanding it is global footprint across every one of the continents. Eye-sight We want to be a research centered global pharmaceutical company not only is it a highly effective generic producer. To discover and develop progressive, value-added items those enhance the quality of life of men and women around the world. And contribute towards growth of each of our Nation.
The primary theme of the business is, “Innovation into practice. Mission Provide persons globally with high quality healthcare products at inexpensive costs in order to increase access to medicine and to offer employees a great enabling environment that facilitates realization of their full potential.
Incepta could anticipate the necessity of the market and supply the right merchandise at the right time. High focus on R, Deb investment in the very beginning authorized the introduction of top quality products ahead of its competitors in most cases. Incepta Pharmaceuticals Limited. is now the next largest organization of the country and named the most effective growing from the top five making company near your vicinity. Established back in 1999, the company has come far. Currently the Zirabo plant contains several buildings with cutting edge technology.
Dedicated cephalosporin making building, a specialized making building for the production of lyophilized goods, insulin and amino acids and newly developed liquid and semisolid making building and large warehouse is also in operation. Incepta now has one of the largest and competent sales team and large circulation network of its own, managed from 18 different places throughout the nation. A many dynamic qualified and dedicated marketing crew comprising of pharmacists and doctors are in the primary of the marketing operation.
These types of highly skilled professionals play an important role in providing the necessary strategic standard for the promotion of its merchandise. Chronology of Events 1998-99 ¢ Dec 16th 1998, the construction from the factory commenced. ¢ September 1999, business office operations started. ¢ January 1999, initially batch of product Neodin S 150 (Ranitidine one hundred and fifty mg tablet) was developed. 2000 ¢ January 2k, sales started out formally. ¢ February 2000, training in the first set of medical representatives started out. ¢ April 2000, with all the launching of Osartil (Losartan Potassium) the first pharmaceutical drug product of Incepta premiered in the market.
The corporation started off in a new path. ¢ A number of other first ever product, Celenta (Celecoxib), Rofenta (Rofecoxib) and Omidon (Domperidone) implemented in the footsteps of Osartil. ¢ A total of 23 fresh generics with 35 delivering presentations were released this year. 4 of these generics were first ever in Bangladesh. ¢ By the end of 2k Incepta was the number thirty first company of the country. 2001 ¢ There was clearly massive reorganization, rearrangement, reshuffling throughout the company. Sales, Division, Marketing Strategy Section, and Manufacturer, all had been reorganized. ¢ A total of 18 new generics with 37 sales pitches were introduced this year. one particular of these generics were first ever in Bangladesh. ¢ At the conclusion of the yr Incepta was ranked the 12th firm of the country. The company a new phenomenal regarding 448% in the previous year (IMS). 2002 ¢ A total of thirty-two new generics with 49 presentations were launched. 18 of these generics were first ever in Bangladesh. ¢ Large expansion project of the stock was imagined. New office for the sales and distribution operation was likewise taking shape. ¢ The corporation registered a fantastic growth of fifty-five. 85% in the previous 12 months. By the end of the year Incepta was ranked the 10th company from the country (IMS). 003 ¢ Incepta maintained introducing ground breaking and newer molecules to the local market. A total of 32 new generics with 48 demonstrations were launched. 18 of the generics were first ever in Bangladesh. ¢ The new workplace (Dhanmondi) to get the sales and division operation was inaugurated. ¢ The company signed up an excellent growth of 28. five per cent over the earlier year (IMS). ¢ At the conclusion of the 12 months Incepta was ranked the 8th firm of the nation (IMS). 2005 ¢ A total of 17 new generics with thirty-two presentations have been launched. 6 of these generics were very first in Bangladesh. The company taken care of an excellent growth of 48. 2% over the previous year (IMS). ¢ The ranking travelled up once again and the firm was rated the sixth largest firm of the region with the top growth charge among the top five (IMS). 2005 ¢ All of us thrived below challenge and excelled in venturing in unexplored grounds and extended to satisfy the customers. Incepta was audited and recognized as a dealer for UNICEF , UNDP. We did start to supply your life saving drugs to UNICEF from Mar, 2005. ¢ A total of 27 fresh generics with 76 delivering presentations were introduced. 2 of such generics were introduced new ever in Bangladesh. ¢ The company maintained an excellent regarding 34. 8% over the previous year (IMS). ¢ The business was positioned 3rd greatest with the maximum growth top among the five (IMS). 2006 ¢ By 06\ Incepta acquired positioned by itself as a modern research focused and know-how based pharmaceutic company focusing on analysis, web design and development of new items. ¢ Incepta successfully began overseas advertising operation via May 06\. ¢ A total of twenty-five new generics with 82 presentations had been launched. of the generics were first ever in Bangladesh. ¢ The company managed an excellent growth of 31. 26% over the past year (IMS). ¢ The corporation maintained the ranking of 3rd largest (IMS). 3 years ago ¢ Incepta pioneered the creation of biotech goods (Human Insulin) and lyophilized products (Pantoprazole injection) in the Bangladesh pharmaceutic market. This was the first time an area pharmaceutical organization produced this sort of highly complex technology product in the country. ¢ A total of 32 fresh generics with 82 delivering presentations were released. 4 of these generics had been first ever in Bangladesh. Promoting, Sales, Syndication and Supervision departments shifted to the completely owned new office premises in Tejgaon, Dhaka. The international regular head office of Incepta started operation in the new office premises about 1st August, 2007. ¢ A marketing and sales team was setup in Myanmar headed by a nation manager in the Marketing Strategy Staff to promote the 35 items registered while using Myanmar FOOD AND DRUG ADMINISTRATION (FDA). ¢ The company maintained a growth of 12. 93% over the previous 12 months (IMS). ¢ The company organised the 3rd greatest ranking (IMS) among the firms. 008 ¢ Continued expenditure in our main strength that may be our manufacturing plant led to acknowledgement from European authorities and January 10, 2008 Incepta attained Euro “Certificate of GMP Compliance”. ¢ 45 new products with 86 presentations were released of which 10 were first ever in Bangladesh. ¢ The rose received GMP certification (General formulations and Cephalosporins) from Kenyan Ministry of Wellness on January 21, 08. ¢ Incepta was as well awarded GMP (Cephalosporins) coming from Ethiopian Ministry of Overall health on July 22, 2008. Incepta listed 51 items in Mongolia on Sept. 2010 26, 2008 (As first Bangladeshi Company). ¢ Incepta registered a few products in Georgia in October 13, 2008 (As first Bangladeshi Company). ¢ In 2008 significant volume of products received registration in several countries. nineteen products coming from Democratic Republic of Congo, 20 goods from Sri Lanka, 22 products from Togo, 8 items from Hong Kong, 20 goods from Mauritania, 6 items from Vietnam, 1 merchandise in Cambodia. ¢ The company maintained a growth of doze. 10% over the previous year (IMS). The company became the 2nd largest (IMS) among the companies operating in Bangladesh. 2009 ¢ Incepta started out venturing in neuro-scientific human vaccines and de las hormonas products. Structure of the Vaccine , Hormones facilities started out on first January 2009 and eighth November 2009 respectively. ¢ Incepta started to be the initially Bangladeshi Organization to receive GMP Complying Certificate coming from Turkey (Tablets, Capsules and Lyophilized products) on January 08, 2009. ¢ Incepta achieved GMP certification in the Ministry of Health, Yemen on May 25, 2009 (Sterile and Non-sterile products). Incepta launched 51 new products in 2009. 4 of the were first ever in Bangladesh pharmaceutical industry. ¢ The organization maintained a fantastic growth of twenty seven. 71% within the previous year (IMS). ¢ The company managed the 2nd greatest (IMS) position in 2009. 2010 ¢ Incepta was accepted and became enlisted with the Copenhagen office of UNICEF, UNDP and UNESCO as global supplier of drugs. ¢ Incepta was granted GMP license from Uganda, National Drug Authority upon 5th September 2010 (Sterile Products, Non-sterile products and Cephalosporin). ¢ Incepta launched 56 product presentations. 0 which were very first in Bangladesh market. ¢ Incepta managed the 2nd major (IMS) position in Bangladesh pharmaceutical market in 2010. The company showed the strongest expansion among the top 12 companies having a growth charge of thirty four. 97% (IMS). 2011 ¢ Incepta is placed to bring in Human Vaccines to the market and become the first Bangladeshi vaccine production company. ¢ Export features emerged as a focus place for Incepta. With above three hundred items registered in several countries export is now started play essential role in the growth of the corporation.
Currently the business exports to 35 countries of the world with many more in the pipeline. ¢ Since starting supply of medicine to UNICEF in Bangladesh, Incepta has always been the largest provider till today. ¢ Approximately June 2011 the company features launched 30 products, six of which are first ever in Bangladesh industry. Incepta’s Progress in Comparison with Neighborhood Pharma Market (IMS* Data) [pic] Beginning in 2000, Incepta has been releasing new and innovative goods at a faster pace than its opponents.
Up to 06 2011 they have already released more than 317 generics having a total of 624 demonstrations. The company creates a wide variety of dose forms covering up nearly all difficulties therapeutic classes. During the last 14 years of procedure Incepta introduced as many as 118 new generics for the first time at any time in Bangladesh. High give attention to quality and timely launch of much needed essential medicines previously not available in the country offers enabled Incepta to become the 2nd largest pharmaceutical company of the country. Creation Facilities
Presently Incepta has one completely operational grow at Zirabo, Savar, Dhaka (Zirabo plant) and another at Dhamrai, Dhaka. The 2nd site is currently under expansion and several jobs of finished formulation device are getting set up. The Zirabo manufacturing plant is located about 35 Km north of Dhaka Metropolis and addresses an area of land regarding 15, 1000 m2. The overall built up creation area is about 300, 500 square feet. Currently the plant consists of a general purpose making building, an ardent cephalosporin making building, and a specialised manufacturing building for the roduction of lyophilized items, insulin and amino acids additionally to several floors dedicated to the production of sturdy dosage forms- tablets and capsules. A newly developed liquid and semisolid developing building is usually in operation at this site. The site as well houses a warehouse intended for raw, presentation and completed goods. To satisfy the elevating demand coming from domestic and overseas market segments, another factory is currently beneath construction with three times the capacity of the existing one.
Another multipurpose building houses the Research , Expansion lab combined with canteen facility. At present many products are originating from this plant at Zirabo. Manufacturing and packaging functions are carried out according to the validated methods through systematically qualified machines with full paperwork at all periods of procedures. The production sites follow the GMP guidelines pertaining to environmental requirements of the developing and the labels area, and comply with the EHS requirements.
Highly advanced HVAC devices are used to state, monitor and supply clean air to the working sector according to the making zone concept, capture and control virtually any dust, vapor, gas or fume made, as well as deal with re-circulated and/or exhausted atmosphere. Temperature and moisture level will be maintained at the desired level through this technique. Design of the area and air-conditioning systems make sure: ¢ Elimination of toxic contamination of the item. ¢ Protection of the environment. ¢ Safety of people. ¢ Prevention with the ingress of vermin, insects, birds and so forth
There are distinct environmental specific zones maintained inside the manufacturing area. Training courses take place frequently according to written plan. Personnel by any means levels experience general GMP and Specialized Training suitable to perform their very own job satisfactorily. Purified normal water and normal water for shot plant and distribution systems are designed to maintain the water top quality according to the relevant requirements and state-of-the-art engineering design including e. g. 24 hours run circulation spiral, smooth home surfaces, satisfactory materials, and minimum stream rates.
With the Zirabo herb the following actions are performed , ¢ Pharmaceutical Production: Processing and packaging of pharmaceuticals to provide to the community market as well as for Export to 3rd get-togethers. Approved suppliers supply the active substances used in manufacturing. Most of the auxiliaries used for production happen to be bought from approved third parties. ¢ Logistics, Warehousing: Storing of raw and packaging supplies to meet the needs of development and also keeping and give of completed products as per concept of Great Storage Practice of pharmaceuticals. Engineering/Industrial Anatomist: In line with pharmaceutic production, overall health safety and environmental protection, infrastructure repair, machinery and other maintenance. Fertilizer treatment and safe disposal of pharmaceutical squander. ¢ Top quality Assurance/Quality Control: Quality Charge of pharmaceuticals, organic and the labels materials, reagents and chemical compounds, plant and personnel care, method and process validation, and overall quality assurance of pharmaceuticals. ¢ Research , Development: Formulation development and adaptation to get scale up production with process validation, method affirmation in collaboration with QA/QC.
Stability examine and shelf life determination of pharmaceutical items. Reformulation/improvement of existing products in line with new/advanced technology. ¢ Plant HR/Administration: Support several units from the plant intended for HR related issues, basic services, general logistics and administrative issues. The following item forms are designed on the creation site of Incepta Pharmaceutical drugs Ltd: A. Sterile Items: Liquid dose forms (LVP , SVP, Terminally made sanitary and aseptically filled ampoule) Eye Drops
Solid dosage forms (Solid fill, Dried out vials and Freeze-Dried Products) B. Non Sterile Items: Liquid serving forms (Oral Liquid, Nasal Solution, and Nasal Spray) Semisolid dose forms (Creams, Ointments, and Gels) Sturdy dosage varieties (Tablets, Pills, Powders, and Granules) C. Biological Items: Aseptically prepared injectables: Erythropoetin, Enoxaparin, Insulin, Insulin Glargine (rDNA), Filgrastim D. Cephalosporins (Dedicated manufacturing facility): Stable dosage forms (Tablets, Capsules, and Powder) Sterile Powder blushes (Aseptically loaded vials) Top quality Management System
The QMS of Incepta Drugs Limited is established in a body to describe their operations in various documents and practices which is based on the guidelines of PICS and WHO guidelines. The high quality Manual describes the Quality Coverage of Incepta Pharmaceuticals Limited. The obligations for the technical areas of Quality Assurance will be defined inside the Quality Manual. It encompasses all actions necessary to make, maintain and verify the quality of drugs. The Quality Assurance of Zirabo Grow consists of Quality Control, Quality Compliance and Quality Security.
The main duties and obligations of Top quality Control had been described inside the Quality Manual and relevant SOPs. The Head of Quality Assurance or his delegates are in charge of for launching drug substances, excipients, dosage forms and packaging materials. Quality Complying is responsible for IPC, GMP co-ordination and teaching. Performances of routine GMP checks are executed as per need, Monitors to respect GMP regulation inside the manufacturing simply by instant investigations of Group Record conclusion, visual checks of cleaning of working place, line measurement, performance checks of harmony , additional equipment.
Quality Surveillance is liable for the setup of the Top quality Management System in several areas in collaboration with different departments. Quality Surveillance enjoy active position in doing external and internal audits with their follow-ups. Research , Development is responsible for formulation creation and technique development, employing technical transfer to Development and Quality Control, and also covers method validation, washing validation, approach validation and follow up stability. The Quality Manual describes just how testing instructions are set up and employed.
The testing instructions include the requirements and testing methods. The testing instructions will be binding intended for release assessment and for followup stability assessment. A schedule inspection has been done in the name of “Self Inspection” mainly interested in safety, sterilization and infra-structural facilities ultimately causing GMP which include documentation. Availability of raw materials is mainly obtained from authorized suppliers. We select and evaluate the dealer as per procedures. This procedure is likewise applicable in the case of supply of Principal and Second Packaging Supplies.
Marketing, Revenue , Syndication A complete and integrated Marketing, Sales and Distribution network is required to associated with information on product or service available to the customer. To achieve the purpose and mission, all of us affirm the values of integrity, admiration for people, advancement, performance and leadership. Around 4000 persons from various disciplines which include pharmacy, microbiology, MBA, Accounting, Engineering and Medicine work nationwide within the umbrella of Incepta. All the skilled and professional workers are set at their very own very suitable responsible positions.
Our sales force comprising remarkably professional science graduate and post-graduate folks are involved in the well-timed and clean promotion of your products for the benefits of each of our doctors, persons as well as the whole nation. Incepta has its own significant distribution network having 18 depots nationwide. They make the merchandise available in every single drug retail store of the country. The depots are located in Dhaka, Chittagong, Rajshahi, Khulna, Sylhet, Barisal, Comilla, Noakhali, Mymensingh, Magura, Bogra, Narayangonj, Rangpur, Dinajpur, Tangail, Jessor, Moulovibazar and Cox’s Transaction.
Products are supplied every day to all the cities and towns of the country. Distant areas are supplied rhythmically to ensure regular availability of products to all consumers. There is a large fleet of transportation including refrigerator trucks pertaining to supplying temperatures sensitive items to selling shops about the country. Chilly chain method is employed to products which need rigid temperature control. Storage of such products is usually maintained using refrigerators with backup power to ensure repair of standardized environment.
Global Reach of Incepta: Incepta marketplace their products in 35 countries of the world through their circulation partners. [pic] Asia: Afghanistan, Armenia, Bhutan, Cambodia, Atlanta, Hong Kong, Laos, Maldives, Mongolia, Myanmar, Sri Lanka, Tajikistan, Turkey, U. A. E. Vietnam Africa: G. R. Congo, Ethiopia, Mauritania, Seychelles, Somalia, Swaziland, Togo, Kenya The european union: Finland, Ukraine North America: Belize, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras South usa: Guyana Oceania: Fiji Foreign Marketing
Incepta, a leading Pharmaceutical drug manufacturer in Bangladesh, carries on its trip towards natural dream to turn into a key factor in the world Pharmaceutical drug market by managing a constant commitment to research, producing innovative products and quality managing. Our unwavering determination to achieve excellence potential clients us to new global benchmarks. Incepta is guided by its export objective to improve the and health of people worldwide. Its corporate and business philosophy is to create fresh value around health-related goods through science and modern technology.
Incepta features always given very high priority to their Research and Development actions. This emphasis enabled Incepta to develop and market 124 generics the first time ever in Bangladesh pharmaceutical market. The company has effectively developed 639 dosage types of 335 generics in different specialties that are currently selling in the local as well as intercontinental market. Incepta is carrying on to introduce new and technologically advanced substances and ground breaking dosage varieties. These substances and dose forms have got played essential role towards the rapid regarding the company within the last eleven years.
Currently Incepta is the second largest and fastest developing company among the most notable five firms of the region. The company is dedicating a substantial percentage of its resources to conditioning its technology including biotechnology, centered on Pharmaceutical drugs. Incepta at present manufactures and sells a number of bio-tech goods in the local marketplace. In order to increase its bio-tech business in another country Incepta has received a state-of-the-art Human Shot production center which will enter into production rapidly.
Within six years of beginning export functions, Incepta right now sells usana products in 45 countries. This has become conceivable due to an intellectual pool area of among the best minds in the country. Starting 5 years ago, Incepta previously has registration of more than three hundred products in different countries around the globe. Further negotiation with feasible business companions and item registration will go on to additional the presence of the business in many more countries. In January 2008, the company received “Certificate of GMP compliance” from Eu which essentially opened the doorway to the Euro market for Incepta.
UK MHRA, the regulatory authority of Britain has inspected the Zirabo plant of Incepta Pharmaceutical drugs Ltd in February 2011. Incepta received the GMP approval because of its solid dose form service in September 2011 due to its own developed products enabling marketing in UK and also other European countries. In 2004 Incepta was examined by UNICEF and UNDP and recognized as a potential supplier. In 2005 Incepta started supplying products to UNICEF in your area in Bangladesh. Subsequently in 2010, Incepta was accepted by global head office of EL agencies at Copenhagen, Denmark and became enlisted as global supplier to UNICEF, UNESCO, UNDP, UNRWA and BEVÖLKERUNGSFOND DER VEREINTEN NATIONEN.
During the course of the very last couple of years the company has received accreditation from a number of other countries of the world and at present holds the subsequent GMP accreditation from their respective Ministry of Health. ¢ UK MHRA GMP Qualification ¢ Eu GMP Qualification ¢ Poultry GMP Qualification ¢ Yemen GMP Qualification ¢ Kenya GMP Qualification ¢ Democratic Republic of Congo GMP Certificate ¢ Ethiopia GMP Certificate ¢ Uganda GMP Certificate ¢ Republic of Sudan Incepta currently provides its product in many countries of Asia, The african continent, Central America and has started to sell in Latin America and Europe.
Incepta is definitely taking special efforts to make sure presence inside the rest of the world. Currently the firm is discovering distributorship, contract manufacturing, in licensing, technology partnership and many other forms of cooperation. Companies around the world can benefit from partnership with Incepta as the business offers a very large profile of universal products available. Focus on ensuring high quality and cost effectiveness makes our portfolio more attractive to potential customers.
